Pathway-Based Drug Repositioning for Cancers: Computational Prediction and Experimental Validation

Area of Science:

• Computational biology
• Pharmacology
• Oncology

Background:

• Developing cost-effective anticancer drugs with minimal toxicity remains a significant challenge in cancer chemotherapy.
• Targeting molecular pathways offers a promising strategy for novel cancer therapeutics.

Purpose of the Study:

• To develop a novel computational approach for drug repositioning using molecular pathways as therapeutic targets for cancer treatment.
• To identify potential anticancer drugs by analyzing gene expression data and predicting pathway modulation.

Main Methods:

• Analyzed gene expression data from 1112 drugs across 66 human cell lines.
• Identified drugs that inactivate cancer-promoting pathways (cell cycle) and activate cancer-cell-death pathways (apoptosis, p53 signaling).
• Performed large-scale prediction of anticancer effects and validated findings using in vitro assays (cell viability, cytotoxicity, apoptosis induction).

Main Results:

• Successfully identified several potential anticancer drugs through the computational and experimental validation process.
• Demonstrated the effectiveness of the pathway-based drug repositioning strategy.

Conclusions:

• The proposed pathway-based computational method shows great potential for improving drug repositioning research in cancer treatment.
• This approach can aid in discovering novel anticancer drugs with potentially lower toxicity and cost.